Endpoints News 5. Mai 2026 Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
Endpoints News 5. Mai 2026 Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
Endpoints News 5. Mai 2026 Microbiome startup raises $48M for immunotherapy and malnutrition treatments